Harmony Biosciences competitors

Dr. Tabuteau has served as our founder, Chief Executive Officer, and Chairman of our board of directors since our founding in January 2012. Prior to founding our company, Dr. Tabuteau was a Senior Analyst and Partner at Healthco/S.A.C. Capital (now known as HealthCor) where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Prior to Banc of America, Dr. Tabuteau was part of the healthcare investment banking group at Goldman Sachs. Dr. Tabuteau earned his M.D. from Yale University School of Medicine and his Bachelor of Arts in molecular biology and biochemistry from Wesleyan University.

Michael Cola joined Medgenics as President and CEO in September 2013. Prior to joining Medgenics, Mr. Cola served as President of Specialty Pharmaceuticals at Shire plc, a global specialty pharmaceutical company, from 2007 until April 2012. He joined Shire in 2005 as EVP of Global Therapeutic Business Units and Portfolio Management. Prior to joining Shire, he was with Safeguard Scientifics, Inc., a growth capital provider to life sciences and technology companies, where he served as President of the Life Sciences Group. While at Safeguard, Mr. Cola served as Chairman and CEO of Clarient, Inc., a cancer diagnostics company subsequently acquired by GE Healthcare, and as Chairman of Laureate Pharma, Inc., a full-service contract manufacturing organization serving research-based biologics companies. Prior to Safeguard Scientifics, Mr. Cola held senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and at AstraZeneca, a global biopharmaceutical company. Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He serves on the Board of Directors of Vanda Pharmaceuticals Inc., Sage Therapeutics, Ben Franklin Technology Partners and Pennsylvania BIO, the statewide association representing the bioscience community. He also currently serves as Chairman of the Board of Governors of the Boys & Girls Clubs of Philadelphia.

Dr. McWilliams is the CEO of Glycomine. He was previously a Managing Director at Sanderling Ventures where he was responsible for its investment in Actimis Pharmaceuticals and, as CEO, led the company into the clinic and through to a successful exit via an acquisition by Boehringer Ingelheim. Prior to joining Sanderling, Dr. McWilliams worked at Genentech where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in pre-clinical and clinical development including the anti-angiogenesis therapeutic, Avastin®. Prior to that he was an Associate with Booz & Co (now PwC) in San Francisco where he focused on consulting projects for major US and International life science companies. Prior to that he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bio-informatics. Dr. McWilliams received an M.B.A. from Columbia Business School, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. and M.A. in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University.

• Member of the National Ernst and Young Entrepreneur of the Year Hall of Fame• Inducted into the University of Texas College of Natural Sciences Hall of Honor• Received Ohio University's School of Business Distinguished Business Award• Received Ohio University Konneker Medal, the highest award given to a faculty member or former student for entrepreneurial excellence• Named one of the top 10 Life Sciences CEOs in Texas by the Texas Healthcare and Bioscience InstituteMr. Hawkins is currently the President and CEO of Lumos Pharma, Inc. an early-stage orphan drug company based in Austin, Texas. He currently serves as a Board of Director for SciClone Pharmaceuticals Inc., a NASDAQ listed company (SCLN), a biopharmaceutical company whose lead product Zadaxin, an adjuvant for the influenza vaccine in immunocompromised patients or as an immune stimulant, has been approved in at least 13 countries.In addition he serves as a Board of Director for Cytori Therapeutics, Inc.; a global leader in stem cell research and the use of adipose derived stem and regenerative cells.Rick Hawkins is a member of the National Ernst and Young Entrepreneur of the Year Hall of Fame.Mr. Hawkins was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas by Dean, Mary Ann Rankin. In 2006 he received Ohio University’s Distinguished Business Achievement Award, and in 2014 was awarded the Konneker Medal, the leading entrepreneurial honor awarded by the University. Rick was named one the top 10 Life Sciences CEO’s in Texas by the Texas Healthcare & Bioscience Institute and was the keynote speaker at BioVenture Showcase 2008.

Thomas Smeenk is a President/CEO at Tyranex Gold Inc, Director at Hemostemix Inc, and Board Member at Hemostemix Inc and is based in Toronto, Ontario, Canada. He has worked as Dir:Business Development at Bullion Management Group Inc, Founder & President also Vice-President Business Development at Theravitae, and VP:Business Development at Memex Inc.. Thomas works or has worked as President/CEO at Ibi Corp. He studied at Western University between 1986 and 1988, CCH between 1975 and 1979, and Carleton University between 1983 and 1985.